Cresilon stock
Private-market facts for current and former Cresilon employees researching their stock.
Overview
Cresilon develops VETIGEL, a plant-based hemostatic gel that stops traumatic and surgical bleeding on contact within seconds, working independently of the body's natural clotting process.
Cresilon outlook
These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.
Selling Cresilon shares
Why shareholders consider selling
Shareholders in Cresilon may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Cresilon does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Cresilon stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Cresilon shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Cresilon shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series B round can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Cresilon shareholders
Exploring equity in Cresilon often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Cresilon most recently raised a Series B round . Total funding raised to date is approximately $68M.
Founders & company background
Cresilon was founded in 2014 by Joe Landolina and is headquartered in Brooklyn, NY.
Industry
Similar private companies
Frequently asked questions
- Is Cresilon still a private company?
- Yes, Cresilon is currently a private company.
- What is Cresilon's latest funding round?
- Cresilon's most recent known round is Series B.
- What is Cresilon's valuation?
- Cresilon's valuation has not been publicly disclosed.
- Who are the investors in Cresilon?
- Investor information is not currently available.
- Can I sell my Cresilon stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Cresilon stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Cresilon data compiled from funding disclosures, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.